On September 29, 2026, KALA Bio (NASDAQ: KALA) announced that it signed a non-binding letter of intent on September 24 to acquire 100% of a privately held U.S. management services organization (MSO) behind a LegitScript-certified, NABP-accredited, provider-led telehealth platform that serves clients in all 50 states. The company did not name the target. Its core business sells therapies across four lanes: weight management (including compounded GLP-1s), hormone health, longevity and sexual wellness. It also offers at-home lab testing and what KALA calls AI-assisted client engagement tools.

Why It Matters

This is what the long tail of the Hims & Hers model looks like when it comes up for sale. By our math, ~$15 million for ~$12.7 million in trailing revenue is roughly **1.2x sales** for a cash-flow-positive, 50-state, accredited platform. That is a modest multiple, and it reflects how the market prices compounded-GLP-1 revenue, which remains under FDA and legal pressure. Sexual wellness (typically ED and related prescriptions) is the bolt-on lane here, not the growth driver. It is still standard in the "men's and women's wellness telehealth" bundle, because it's recurring, cash-pay and cheap to fulfil. For investors in ED and hormone telehealth, the pattern to note is consolidation by public shells and pivoting microcaps buying revenue rather than building it. Until a definitive agreement names the target and audited numbers appear, treat this as an LOI with stated terms, not a deal. The regulatory risk on compounded GLP-1s is the biggest variable in whether it closes at this price.

The numbers come from the target's management and are unaudited. Revenue was about $12.7 million for the trailing twelve months to August 2026, total sales since the 2023 founding exceed $48 million, and the platform has served more than 90,000 clients. KALA describes it as cash-flow positive. The proposed price is about $15 million in a mix of cash and KALA stock, with the cash coming from KALA's balance sheet. A 45-day due-diligence period is expected to end in November 2026, with definitive agreements and closing targeted for late 2026 or early 2027. Existing management would stay on.

KALA's CEO and CFO, Avi Minkowitz, said the deal "would add an established, revenue-generating platform to KALA's operating business." KALA also plans to use the platform as a direct-to-consumer channel for genetic-testing products it distributes under a Virotek agreement, and to evaluate integrating the target's AI stack into its own Researgency.ai work.

Sources

Update — 2026-09-30

Initial entry — story first created.